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Abstract
Background: Activation of microglia cells plays an important role in neurological diseases.
Positron emission tomography (PET) with [
11C]-(R)-PK11195 has already been used to visualize
activated microglia cells in neurological diseases. However, [
11C]-(R)-PK11195 may not
possess the required sensitivity to visualize mild neuroinflammation. In this study, we evaluated
the PET tracers [
11C]-DPA-713 and [
18F]-DPA-714 as agents for imaging of activated microglia
in a rat model of herpes encephalitis.
Materials and Methods: Rats were intranasally inoculated with HSV-1. On day 6 or 7 after
inoculation, small animal PET studies were performed to compare [
11C]-(R)-PK11195, [
11C]-
DPA-713, and [
18F]-DPA-714.
Results: Uptake of [
11C]-DPA-713 in infected brain areas was comparable to that of [
11C]-(R)-
PK11195, but [
11C]-DPA-713 showed lower non-specific binding. Non-specific uptake of [
18F]-
DPA-714 was lower than that of [
11C]-(R)-PK11195. In the infected brain, total [
18F]-DPA-714
uptake was lower than that of [
11C]-(R)-PK11195, with comparable specific uptake.
Conclusions: [
11C]-DPA-713 may be more suitable for visualizing mild inflammation than [
11C]-
(R)-PK11195. In addition, the fact that [
18F]-DPA-714 is an agonist PET tracer opens new
possibilities to evaluate different aspects of neuroinflammation. Therefore, both tracers warrant
further investigation in animal models and in a clinical setting.
Key words: Positron emission tomography, Neuroinflammation, Microglia, [
11C]-PK11195, TSPO
Introduction
N
eurological disorders are a significant burden to society
worldwide, especially in countries where a growing
proportion of the population is over 65 years old [1]. Despite
the large difference between neurological disorders, neuro-
inflammation is involved in both acute pathology, such as
stroke and herpes encephalitis, and chronic neurodegener-
ative diseases, such as Parkinson’s and Alzheimer’s disease.
Although neuroinflammation was found to be involved in
neurological disorders, it is still not known when the Correspondence to: Janine Doorduin; e-mail: j.doorduin@ngmb.umcg.nlinflammatory response is beneficial, detrimental, or inciden-
tal. Nakajima and Kohsaka [2] proposed that neuroinflam-
mation in acute injuries is beneficial, whereas it will lead to
neuronal cell death in chronic diseases. When the exact role
of neuroinflammation in different neurological disorders is
unraveled, this will inevitably lead to early diagnosis,
possible therapeutic intervention, and improved treatment.
One of the key players in neuroinflammation is the
microglia cell, which provides the first line of defense
against brain tissue injuries. In the healthy central nervous
system, microglia cells continuously survey their microen-
vironment by rapid extension and extraction of their ramified
processes [3, 4]. In response to a wide variety of central
nervous system insults, microglia cells become activated and
change from their ramified state into amoeboid morphology.
The activation of microglia cells is accompanied by an
increased expression of the translocator protein (TSPO), an
18 kDa component of a heteromeric complex. The expres-
sion of the TSPO is low in the healthy brain, but is highly
upregulated in neuroinflammation.
Positron emission tomography (PET) is a non-invasive
imaging technique that can be used to study the role of
neuroinflammation in neurological disorders, using the TSPO
as a biomarker. PET has already been used in numerous
clinical studies to visualize activated microglia cells using the
isoquinoline [
11C]-(R)-PK11195 ((R)-N-methyl-N-(1-methyl-
propyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide) as
the tracer. [
11C]-(R)-PK11195 is a ligand for the TSPO.
Although [
11C]-(R)-PK11195 has already been used to image
activated microglia cells in, among others, stroke [5–8], mul-
tiple sclerosis [9–12], herpes encephalitis [13], Parkinson’s
disease [14, 15], and Alzheimer’s disease [16–18], it is not an
ideal tracer, since it shows low brain uptake and high non-
specific binding. Pharmacokinetic modeling of the PET data
is complicated and [
11C]-(R)-PK11195 may not possess the
sensitivity to visualize mild neuroinflammation, which makes
it unsuitable for use in early diagnosis and detection of subtle
effects of therapeutic intervention.
Therefore, a more sensitive and specific PET tracer for
TSPO imaging wouldbeofgreat interest.Pyrazolopyrimidines
display high affinity for the TSPO and two compounds from
this class have already been radiolabeled for use in PET. The
pyrazolopyrimidines DPA-713 and DPA-714 have higher
affinity for the TSPO in vitro (Ki=4.7 nM and Ki=7.0 nM,
respectively) than PK11195 (Ki=9.3 nM) [19–21]. The TSPO
antagonistDPA-713was labeledwith carbon-11and evaluated
in vivo in a healthy baboon [22]. It was concluded that [
11C]-
DPA-713 is a specific ligand for the TSPO and that it may be
useful for studying changes in the density of TSPO binding
sites. In addition, [
11C]-DPA-713 exhibited a higher signal-
to-noise ratio than [
11C]-(R)-PK11195 in a rat model of
neurodegeneration, which makes it more suitable for quantifi-
cation of TSPO binding sites [23]. The TSPO agonist, DPA-
714, was labeled with fluorine-18 and demonstrated good
uptake in the primate brain and an eightfold higher uptake in
the lesioned striatum of a quinolinic acid-lesioned rat model of
activated microglia [19, 20]. This higher uptake was shown to
be selective TSPO binding.
Both[
11C]-DPA-713and[
18F]-DPA-714havedemonstrated
better imaging properties than [
11C]-(R)-PK11195 in striatum-
lesioned rats [19, 20, 23]. However, striatum lesion by injection
of a toxic compound requires invasive manipulations to
generate an inflammatory response. The aim of this study was
to validate these tracers in a different rat model that does not
require invasive manipulation and unnatural toxic compounds
to evoke neuroinflammation, which may better mimic microglia
activation in neurological disorders. Therefore, [
11C]-DPA-713
and [
18F]-DPA-714 were evaluated in a rat model of herpes
encephalitis (HSE) and compared to [
11C]-(R)-PK11195.
Materials and Methods
[
11C]-(R)-PK11195
[
11C]-(R)-PK11195 was labeled by trapping [
11C]-methyl iodide
[24] in a solution of 1 mg (R)-N-desmethyl PK11195 and 10 mg
potassium hydroxide in 300 μl dimethylsulfoxide. The reaction
mixture was allowed to react for 1 min at 40°C, neutralized with
1 M HCl, and passed through a 45-μm Millex HV filter. The
filtrate was purified by high-performance liquid chromatography
(HPLC) using a μBondapak C18 column (7.8×300 mm) with
acetonitrile/25 mM NaH2PO4 (pH 3.5) (55/45) as the eluent (flow
5 ml/min). To remove the organic solvents from the product, the
collected HPLC fraction (retention time 7 min) was diluted with
100 ml of water and passed through an Oasis HLB 30 mg (1 cc)
cartridge. The cartridge was washed twice with 10 ml of water and
subsequently eluted with 0.7 ml of ethanol and 5 ml of water. The
product was sterilized by filtration over a 22 μm Millex LG filter.
The product was obtained in 33±15% radiochemical yield (n=11).
Quality control was performed by HPLC, using a Novapak C18
column (150×3.9 mm) with acetonitrile/25 mM NaH2PO4 (pH 3.5;
60/40) as the eluent at a flow of 1 ml/min. The radiochemical purity
was always 995% and the specific activity was 51±18 MBq/nmol.
[
11C]-DPA-713 (Compound 2)
For the preparation of N,N-diethyl-2-(2-(4-[
11C]methoxyphenyl)-5,7-
dimethylpyrazolo(1,5-α)pyrimidin-3-yl)acetamide (compound 2,
[
11C]DPA-713), [
11C]-methyl triflate was trapped in a solution of
1m gN,N-diethyl-2-(2-(4-hydroxyphenyl)-5,7-dimethylpyrazolo(1,5-
α)pyrimidin-3-yl)acetamide (compound 1) [22] and 2.5 μl 0.5 M
NaOH in 0.5 ml of acetonitrile (Fig. 1). After 5 min at 100°C, the
reaction mixture was diluted with 0.5 ml of acetonitrile and 1 ml of
water and purified by HPLC using a SymmetryPrep C18 column
(7 μm, 7.8×300 mm) and acetonitrile/0.1 M NaH2PO4 (1/1) as the
eluent (flow 5 ml/min). The radioactive product with a retention time
of 7–8 min was collected. The product was diluted with 100 ml of
water and passed through an Oasis HLB 30 mg (1 cc) cartridge. The
cartridge was washed twice with 10 ml of water and subsequently
eluted with 0.7 ml of ethanol and 5 ml of water. The product was
sterilized by filtration over a 22-μm Millex LG filter. The product is
obtained in 48±15% radiochemical yield (n=10). Quality control was
performed by HPLC, using a Novapak C18 column (150×3.9 mm)
with acetonitrile/25 mM NaH2PO4 (40/60) as the eluent at a flow of
1 ml/min. The radiochemical purity of [
11C]DPA-713 was always
999% and the specific activity was 41±12 MBq/nmol.
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5,7-dimethylpyrazolo(1,5-α)pyrimidin-3-yl)
acetamide (Compound 3)
To a suspension of 42 mg 55% NaH (1.0 mmol) in 15 ml freshly
distilled tetrahydrofuran (THF), 100 mg (0.44 mmol) of N,N-diethyl-2-
(2-(4-hydroxyphenyl)-5,7-dimethylpyrazolo(1,5-α)pyrimidin-3-yl)acet-
amide (compound 1) [22] was added (Fig. 1). After the reaction mixture
was refluxed for 30 min, a solution of 300 mg (0.87 mmol) ethyl-
eneglycol ditosylate in 20 ml THF was quickly added to the hot reaction
mixture. After another 18 h of refluxing, the reaction flask was cooled
oniceandthereactionwasquenchedbyslowlyadding50mlofwater.
The mixture was extracted three times with 25 mlof dichloromethane.
The combined organic layers were washed with 50 ml of water, dried
onanhydroussodiumsulfate,andfiltered.Theproductwaspurifiedby
flash column chromatography (silica gel), using 3% methanol in
dichloromethane as the eluent. The product was obtained as a light
yellow solid in 59% yield (140 mg).
1H-NMR (CDCl3, 200 MHz): δ
7.83 (d, 2H, J=8.1Hz,tosyl),7.74 (d, 2H,J=8.8 Hz, Ar), 7.35 (d,2H,
J=8.1 Hz, tosyl), 6.86 (d, 2H, J=8.8 Hz, Ar), 6.52 (s, 1H, Ar), 4.39
(t, 2H, J=4.6 Hz, CH2O), 4.19 (t, 2H, J=4.6 Hz, CH2O), 3.95 (s, 2H,
CH2C=O), 3.51 (q, 2H, J=7.1 Hz, CH2N), 3.40 (q, 2H, J=7.1 Hz,
CH2N), 2.75 (s, 3H, CH3), 2.58 (s, 3H, CH3), 2.45 (s, 3H, tosyl), 1.21
(t, 3H, J=7.1 Hz, CH2CH3), 1.11 (t, 3H, J=7.1 Hz, CH2CH3).
N,N-diethyl-2-(2-(4-[2-fluoro-1-ethoxy]phenyl)-
5,7-dimethylpyrazolo(1,5-α)pyrimidin-3-yl)
acetamide (Compound 4, DPA-714)
Reference material of DPA-714 (compound 4) was prepared as
described for compound 3, except 2-fluoroethyl tosylate was used as
the alkylating agent instead ofethyleneglycolditosylate(Fig.1). Yield
was 80% (light yellow solid).
1H-NMR (CDCl3,2 0 0M H z ) :δ 7.74 (d,
2H, J=8.1 Hz, Ar), 6.99 (d, 2H, J=8.1 Hz, Ar), 6.54 (s, 1H, Ar), 4.77
(dd, 2H, J=2.9 Hz, J=47.6 Hz, CH2F), 4.26 (dd, 2H, J=2.9 Hz, J=
27.5 Hz, CH2O ) ,4 . 0 5( s ,2 H ,C H 2C=O), 3.51 (q, 2H, J=7.0Hz,CH2N),
3.41 (q, 2H, J=7.0 Hz, CH2N ) ,2 . 7 8( s ,3 H ,C H 3), 2.64 (s, 3H, CH3),
1.23 (t, 3H, J=7.0Hz,CH2CH3), 1.12 (t, 3H, J=7.0Hz,CH2CH3).
[
18F]-DPA-714 ([
18F]-Compound 4)
[
18F]Fluoride was eluted from a Waters QMA anion exchange
cartridge with 5 mg potassium carbonate in 1 ml of water and
collected into a vial containing 20 mg kryptofix[2.2.2]. [
18F]KF/
kryptofix[2.2.2] was dried by azeotropic distillation with acetoni-
trile at 130°C. A solution of 1 mg compound 3 in 0.5 ml dry DMF
was added to the [
18F]KF/kryptofix complex. The reaction mixture
was allowed to react for 10 min at 100°C. After cooling, the
reaction mixture was diluted with water and HPLC eluent
(acetonitrile/0.1 M NaH2PO4 (45/55)) and passed through an
Alumina N seppak to remove the majority of unreacted [
18F]
fluoride. The product was purified by HPLC using a SymmetryPrep
C18 column (7 μm, 7.8×300 mm) with acetonitrile/0.1 M
NaH2PO4 (45/55) as the eluent (flow 5 ml/min). To remove the
organic solvents from the product, the collected HPLC fraction
(retention time 11 min) was diluted with 15 ml of water and passed
through an Oasis HLB 30 mg (1 cc) cartridge. The cartridge was
washed with 5 ml of water and subsequently eluted with 0.7 ml of
ethanol and 5 ml of water. The product was sterilized by filtration
over a 22-μm Millex LG filter. The product was obtained in 17±
8% radiochemical yield. Quality control was performed by HPLC,
using a Novapak C18 column (150×3.9 mm) with acetonitrile/
25 mM NaH2PO4 (35/65) as the eluent at a flow of 1 ml/min. The
radiochemical purity was 999% and the specific activity was 80±
35 MBq/nmol (n=11).
Fig. 1. Synthesis of DPA-713 from the labeling precursor compound 1 and DPA-714 from the labeling precursor compound 3.
The labeling precursor compound 3 and the reference material for DPA-714 were synthesized from compound 1 using
ethyleneglycol ditosylate and 2-fluoroethyltosylate as the alkylating agent, respectively.
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Male outbred Wistar-Unilever (SPF) rats (weight 287±38 g) were
obtained from Harlan (Lelystad, The Netherlands). The rats were
individually housed in Macrolon cages (38×26×24 cm) on a layer
of wood shavings in a room with constant temperature (21±2°C)
and fixed, 12-h light–dark regime. Food (standard laboratory chow,
RMH-B, Hope Farms, The Netherlands) and water were available
ad libitum. After arrival, the rats were allowed to acclimatize for at
least 7 days. The rats were randomly divided into nine groups:
control rats (control) scanned with either [
11C]-(R)-PK11195 (n=5),
[
11C]-DPA-713 (n=5), or [
18F]-DPA-714 (n=5), rats infected with
HSV-1 (HSE) scanned with either [
11C]-(R)-PK11195 (n=9),
[
11C]-DPA-713 (n=9), or [
18F]-DPA-714 (n=9), and rats infected
with HSV-1 and pre-treated with PK11195 (HSE pre-treated with
PK11195) scanned with either [
11C]-(R)-PK11195 (n=4), [
11C]-
DPA-713 (n=4), or [
18F]-DPA-714 (n=4). After PET scanning, the
rats were killed and the ex vivo biodistribution of the tracers was
determined. The study was approved by the Animal Ethics
Committee of the University of Groningen, The Netherlands.
HSV-1 Inoculation
The HSV-1 strain was obtained from a clinical isolate, cultured in
Vero cells and assayed for plaque forming units (PFU) per
milliliter. The rats were slightly anaesthetized with 5% isoflurane
(Pharmachemie BV, The Netherlands) and inoculated with HSV-1
by the application of 100 μl of phosphate-buffered saline (PBS)
with 1×10
7 PFU of virus on the nostrils (50 μl per nostril) with a
micropipette. Control rats were treated similarly by the application
of 100 μl PBS without virus. Clinical symptoms in all rats were
scored daily after the inoculation by the same observer.
Immunohistochemistry
Immunohistochemical staining was performed in control and HSV-
1-infected rats on day 7 after inoculation. The rats were euthanized
and the brains were removed and frozen at −80°C. Coronal brain
sections of 10 μm were cut at −18°C using a cryostat (Leica
Microsystems, Germany). Sections were collected on slides,
vacuum-dried, fixated for 20 min in paraformaldehyde (4% in
100 nM PBS), and washed three times for 5 min in 100 nM PBS.
To block non-specific binding, sections were incubated with 5%
normal goat serum in PBS containing 3% triton and washed for
5 min in 100 nM PBS. Sections were incubated overnight at 4°C
with the primary antibody (Anti Iba1 Rabbit (1:750), Wako
Chemicals, USA). After incubation, sections were washed three
times for 5 min in 100 nM PBS and incubated for 1 h with the
secondary antibody (FITC-conjugated Goat Anti Rabbit IgG
(1:250), Jackson ImmunoResearch Laboratories Inc., USA) in 1%
normal goat serum in PBS containing 3% triton. As a negative
control, sections were only incubated with the secondary antibody.
Subsequently, sections were washed three times for 5 min in PBS
and mounted with Mowiol mounting medium. The fluorescence
was examined by using a microscope (Zeiss Axioskop 2, Carl Zeiss
Microimaging Inc., Germany) in combination with the Leica
Application Suite (Version 2.3.3 R1, Leica, Germany).
PET Studies
PET scans were performed when robust clinical signs of infection
appeared, which was either on day 6 or on day 7 after the
inoculation with HSV-1. The rats were anesthesized by an
intraperitoneal injection of medetomidine (Domitor, Pfizer, The
Netherlands, 0.2 mg/kg) and ketamine (Ketanest, Pfizer, The
Netherlands, 25 mg/kg), after which the rats were positioned in
the small animal PET camera (Focus 220, Siemens Medical
Solutions USA, Inc.) in transaxial position with their heads in the
field of view. A transmission scan of 515 s with a Co-57 point source
was obtained for the correction of attenuation by tissue. After the
transmission scan was completed, the PET tracer [
11C]-(R)-PK11195
(65±22 MBq, 0.71±0.48 μg), [
11C]-DPA-713 (82±23 MBq, 0.91±
0.31 μg), or [
18F]-DPA-714 (37±12 MBq, 0.36±0.18 μg) was
injected via the penile vein. Simultaneous with the injection of the
PET tracer, an emission scan of 62 min was started for [
11C]-(R)-
PK11195 and [
11C]-DPA-713, and a PET scan of 120 min for [
18F]-
DPA-714. In the pre-treated group, unlabeled PK11195 (Sigma-
Aldrich, USA, 5 mg/kg in dimethylsulfoxide at a concentration of
10mg/ml)was administered viathetailvein5min priortoinjectionof
the PET tracer.
The list-mode data of the emission scans was separated into 21
frames (8×30, 3×60, 2×120, 2×180, 3×300, and 3×600 s) for
[
11C]-(R)-PK11195 and [
11C]-DPA-713, and into 28 frames for
[
18F]-DPA-714 (8×30, 4×60, 3×120, 2×180, 4×300, and 8×
600 s). Emission sinograms were iteratively reconstructed
(OSEM2d, four iterations) after being normalized, corrected for
attenuation, and corrected for decay of radioactivity.
PET Image Analysis
PET image analysis was performed using the Clinical Applications
Packaging Program (CAPP5). Regions of interest were drawn
around the bulbus olfactorius, frontal cortex, striatum, parietal/
temporal/occipital cortex, brainstem, and cerebellum in a template
PET scan that was co-registered with the PET scan of interest by
image fusion. The time–activity curves per region of interest were
determined in becquerel per cubic centimeter units and converted
into standardized uptake values (SUV), defined as: [tissue activity
concentration (MBq/g)]/[(injected dose (MBq)/body weight (g)]. It
was assumed that 1 cm
3 of brain tissue equals 1 g. To correct for
the activity in plasma, each point on the time–activity curve (SUV)
was divided by the ex vivo plasma uptake (SUV) at t=60 min for
[
11C]-(R)-PK11195 and [
11C]-DPA-713, and at t=120 min for
[
18F]-DPA-714 creating a tissue/plasma ratio.
Ex Vivo Biodistribution
After the PET scan, the rats were killed by extirpation of the heart
while under deep anesthesia. The brain was dissected into several
brain areas, peripheral organs were excised, and blood was
centrifuged to collect a plasma sample. The brain areas, peripheral
organs, and plasma were weighed and analyzed for the amount of
radioactivity by using a gammacounter (LKB Wallac, Turku,
Finland). Tracer uptake is expressed as the SUV.
To correct for activity of the tracers in plasma, the tissue/plasma
ratio was calculated by dividing the uptake (SUV) in the different
brain areas by the plasma uptake (SUV), for all rats individually.
Subsequently, the TSPO-specific uptake was calculated for control
and HSE rats. The specific uptake was calculated by subtracting the
average tissue/plasma ratio of the HSE rats pre-treated with
PK11195 from the tissue/plasma ratio of control and HSE rats, for
each rat individually.
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All data are expressed as mean ± standard deviation. Statistical
analysis was performed using SPSS for Windows, version 14.0.2.
Statistical analysis on differences between the uptake of [
11C]-(R)-
PK11195, [
11C]-DPA-713, and [
18F]-DPA-714, which were
obtained from the PET scan, was performed by one-way ANOVA.
Per brain area, a Bonferonni post hoc test was used to determine if
there were differences in uptake between the PET tracers. For the
ex vivo biodistribution, statistical analysis on differences in uptake
between control rats, HSE rats, and HSE rats pre-treated with
PK11195 was performed by one-way ANOVA, using a Bonferonni
post hoc test to compare the three conditions per brain area.
Statistical analysis on differences between non-specific and specific
uptake of [
11C]-(R)-PK11195, [
11C]-DPA-713, and [
18F]-DPA-714
was performed by one-way ANOVA, using a Bonferonni post hoc
test to compare the uptake of the PET tracers per brain area. The
time–activity curves were analyzed with the repeated measures
general linear model of SPSS (version 14.0.2) using a Bonferroni
post hoc test per brain area. Correlations of specific binding in
control rats for [
11C]-(R)-PK11195, [
11C]-DPA-713, and [
18F]-
DPA-714 with [
3H]-PK11195 binding as determined by Kurumaji
et al. [25] were assessed with Pearson’s product moment correlation
coefficient (r). Significance was reached when the p value was
G0.05.
Results
Clinical Symptoms
Clinical symptoms were scored daily up to 7 days post-
inoculation and categorized into the following clinical
scores: (0), no symptoms; (1), ruffled fur and irritated
mouth, nose, and eyes; (2), behavioral signs, like stress and
lethargy, and hunched posture; (3), posterior paralysis and
impairment of motor function; and (4), severe paralysis,
labored breathing or death. The first clinical symptoms in the
HSE rats were seen on day 4 or 5 after inoculation with
HSV-1, after which the severity of the symptoms increased.
For both [
11C]-(R)-PK11195 and [
11C]-DPA-713, most rats
had a score of 2 at the day of scanning, whereas most rats
scanned with [
18F]-DPA-714 had a score of 3. The average
of the scores (2.44±0.73 for [
11C]-(R)-PK11195, 2.11±0.78
for [
11C]-DPA-713 and 2.67±0.71 for [
18F]-DPA-714) did
not differ significantly between groups. None of the control
rats showed any clinical symptoms.
Immunohistochemistry
At day 7 after inoculation with HSV-1, intense microglial
activation was observed in the bulbus olfactorius, cerebellum,
and brainstem (Fig. 2). In addition, mild microglial activation
was also seen in the frontal cortex and hippocampus of HSV-
1-infected rats. The activated microglia cells could be
recognized by the rounded shape with short processes,
showing that the microglia cells had converted to the
macrophage-like state. Microglial activation in the brainstem
was observed throughout the whole brainstem and could not
be attributed to a specific area. In control rats, only ramified,
resting microglia cells were observed in all brain areas.
Small Animal PET Imaging
The standardized uptake values obtained from the last
10 min of the PET scans are displayed in Table 1. The
uptake of [
11C]-(R)-PK11195 in the last 10 min of the scan
was significantly higher in the bulbus olfactorius, frontal
cortex, parietal/temporal/occipital cortex, cerebellum, and
brainstem in HSE rats when compared to control rats. The
uptake was consistent with the immunohistochemistry data.
The [
11C]-(R)-PK11195 uptake in the rats pre-treated with
PK11195 was significantly decreased in the bulbus olfactorius,
cerebellum, and brainstem. For [
11C]-DPA-713, a significant
increase in tracer uptake was found in the brainstem and a non-
significant increase in the bulbus olfactorius of HSE rats, as
compared to control rats. Also, [
11C]-DPA-713 showed a
statistically significant reduction in uptake by pre-treatment
withPK11195inthebulbusolfactorius,frontalcortex,parietal/
temporal/occipital cortex, cerebellum and brainstem. The
uptake of [
18F]-DPA-714 derived from the PET scan was
found to be non-significantly higher in the bulbus olfactorius
and brainstem in HSE rats, as compared to control rats. No
effective blocking of [
18F]-DPA-714 by pre-treatment with
PK11195 was found. The PET scan of [
18F]-DPA-714 was
120 min, while the PET scan of both [
11C]-(R)-PK11195 and
[
11C]-DPA-713 was 60 min. For comparison, the uptake [
18F]-
DPA-714 was also determined at 60 min, but no statistically
significant differences were found between the uptake of [
18F]-
D P A - 7 1 4a t6 0a n d1 2 0m i n .
The time–activity curves of the brainstem are displayed in
Fig. 3, to show the kinetics of the tracer over time. These
time–activity curves were normalized for activity in plasma
because tracer uptake in the brain is dependent on the tracer
delivery from plasma. A change in plasma activity concen-
tration due to, for example, pre-treatment with PK11195 can
thus influence brain uptake. For plasma activity normal-
ization, the uptake (SUV) on each individual time point was
divided by the activity in plasma (SUV) as determined ex
vivo on t=60 for [
11C]-(R)-PK11195 and [
11C]-DPA-713,
and on t=120 for [
18F]-DPA-714. Post hoc analysis of the
repeated measures general linear model revealed that the
time–activity curve of [
11C]-(R)-PK11195 in the brainstem
of HSE rats was significantly higher than that of control rats
(pG0.005) and rats pre-treated with PK11195 (pG0.005).
For [
11C]-DPA-713, the time–activity curve in HSE rats was
significantly higher than in the control rats (pG0.05) and in
rats pre-treated with PK11195 (pG0.005). In addition, the
uptake of [
11C]-DPA-713 over time was significantly
reduced by pre-treatment with PK11195, even when com-
pared to control rats (pG0.05). No differences in time–
activity curves of control, HSE, and pre-treated rats were
found for [
18F]-DPA-714 in the brainstem, although pre-
treatment with PK11195 non-significantly reduced the
uptake in the brainstem.
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An ex vivo biodistribution study of the three PET tracers
was performed to confirm the results of the PET studies. In
addition, biodistribution allows investigation of uptake in
smaller brain areas than is possible with small animal PET
imaging. The ex vivo biodistribution, expressed as mean
SUV ± SD, was consistent with the results obtained from the
PET images. Uptake of [
11C]-(R)-PK11195 (Table 2) in the
bulbus olfactorius was increased in HSE rats as compared to
control rats (1.59 vs. 1.20); however, this increase did not
reach statistical significance. A significant increase of [
11C]-
Table 1. Standardized uptake values (mean ± SD) obtained from the last 10 min of the PET scan of [
11C]-(R)-PK11195, [
11C]-DPA-713, and [
18F]-DPA-714
in control rats (control; n=5), rats infected with HSV-1 (HSE; n=9) and rats infected with HSV-1 pre-treated with 5 mg/kg PK11195 5 min before tracer
injection (HSE + PK11195; n=5)
[
11C]-(R)-PK11195 [
11C]-DPA-713 [
18F]-DPA-714
Control
Brainstem 0.50±0.11 0.65±0.17 0.51±0.16
Bulbus olfactorius 0.70±0.16 0.74±0.20 0.57±0.18
Cerebellum 0.41±0.06 0.47±0.03 0.39±0.04
Frontal cortex 0.45±0.07 0.44±0.17 0.30±0.10
Parietal/temporal/occipital cortex 0.35±0.09 0.41±0.08 0.31±0.05
Striatum 0.29±0.07 0.29±0.06 0.19±0.04
HSE
Brainstem 1.52±0.33** 1.23±0.42* 0.84±0.45
Bulbus olfactorius 1.29±0.33** 1.10±0.30 0.82±0.30
Cerebellum 1.02±0.24** 0.82±0.33 0.41±0.22
Frontal cortex 0.74±0.19* 0.60±0.13 0.41±0.18
Parietal/temporal/occipital cortex 0.54±0.14* 0.44±0.12 0.32±0.09
Striatum 0.47±0.13 0.34±0.11 0.23±0.06
HSE + PK11195
Brainstem 0.76±0.04**** 0.27±0.11**** 0.44±0.07
Bulbus olfactorius 0.59±0.07**** 0.33±0.10**** 0.66±0.20
Cerebellum 0.64±0.09*** 0.26±0.07*** 0.48±0.05
Frontal cortex 0.62±0.07 0.27±0.10**** 0.46±0.13
Parietal/temporal/occipital cortex 0.56±0.06 0.21±0.05*
, *** 0.44±0.07*
, ***
Striatum 0.61±0.12* 0.20±0.06 0.37±0.09**
, ***
*pG0.05 as compared to control, **pG0.005 as compared to control, ***pG0.05 as compared to HSE, ****pG0.005 as compared to HSE
Fig. 2. Images (×400) of immunohistochemical staining of microglia cells with Iba, on day 7 after inoculation. For rats infected
with HSV-1 (HSE) microglia are shown in the bulbus olfactorius, frontal cortex, hippocampus, cerebellum, and brainstem (a–e).
For control rats, only the brainstem (f) is shown. The staining in this brain area is representative for the staining in all other brain
areas of control rats.
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found in the medulla (1.29 vs.0 . 6 1 ,p=0.004), pons (1.54 vs.
0.59, pG0.001),andcerebellum(0.88vs.0 . 51 ,p=0.001).[
11C]-
(R)-PK11195 binding to the TSPO was blocked by admin-
istration of unlabeled PK11195, resulting in a significantly
lower uptake of [
11C]-(R)-PK11195 in the medulla, pons,
cerebellum, and bulbus olfactorius.
The ex vivo biodistribution of [
11C]-DPA-713 is shown
in Table 3. As was found for [
11C]-(R)-PK11195, the bulbus
olfactorius in HSE rats showed an increase in [
11C]-DPA-
Fig. 3. Time–activity curves (left) of the brainstem for [
11C]-(R)-PK11195 (a), [
11C]-DPA-713 (b), and [
18F]-DPA-714 (c), and
small animal PET images (right) of control rats (control), rats infected with HSV-1 (HSE), and rats infected with HSV-1 injected
with 5 mg/kg PK11195 5 min before tracer injection (HSE + PK11195). The time–activity curves are expressed as tissue uptake
divided by the ex vivo plasma uptake at t=60 for [
11C]-(R)-PK11195 and [
11C]-DPA-713, and at t=120 for [
18F]-DPA-714.
Statistically significant differences are indicated by *pG0.05 and †pG0.005. The small animal PET images display a coronal
plane of the rat head at the level of the brainstem, in which the brain is delineated by a dashed line. The images are summed
images between 16 and 60 min for [
11C]-(R)-PK11195 and [
11C]-DPA-713, and between 12 and 120 min for [
18F]-DPA-714.
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but this difference did not reach statistical significance.
Uptake in the medulla (1.09 vs. 0.46, p=0.039) and the pons
(1.12 vs. 0.46, p=0.004) of HSE rats was significantly
elevated as compared to control rats. This was confirmed by
blocking studies. Unlabeled PK11195 significantly reduced
[
11C]-DPA-713 uptake in the bulbus olfactorius, pons, and
medulla. The uptake of [
11C]-DPA-713 in control rats was
on average 26% lower (pG0.005) than the uptake of [
11C]-
(R)-PK11195, suggesting less non-specific binding. In
addition, the brain uptake in PK11195 pre-treated rats was
significantly lower for [
11C]-DPA-713 than for [
11C]-(R)-
PK11195 (pG0.005).
[
18F]-DPA-714 uptake (Table 4) in control rats was
significantly lower than [
11C]-(R)-PK11195 uptake (on
average 41%, pG0.005). Significantly increased uptake of
[
18F]-DPA-714 was found in the medulla of HSE rats (0.40
vs. 0.81, p=0.004), when compared to control rats, while a
non-significant increase in uptake was found in the bulbus
olfactorius (0.55 vs. 0.88). No effective blocking of [
18F]-
DPA-714 uptake was found after administration of unlabeled
PK11195.
Ex vivo biodistribution in peripheral organs showed a
high uptake of [
11C]-(R)-PK11195, [
11C]-DPA-713, and
[
18F]-DPA-714 in TSPO expressing organs, like the lungs
and adrenals. In both the lungs and adrenals, [
11C]-(R)-
Table 2. Ex vivo biodistribution of [
11C]-(R)-PK11195, expressed as standardized uptake values (SUV; mean ± SD), 60 min after tracer injection in control rats
(control; n=5), rats infected with HSV-1 (HSE; n=9), and rats infected with HSV-1 pre-treated with 5 mg/kg PK11195 5 min before tracer injection (HSE +
PK11195; n=4)
Control HSE HSE + PK11195
Brain
Amygdala/piriform cortex 0.37±0.11 0.40±0.11 0.49±0.08
Bulbus olfactorius 1.20±0.37 1.59±0.51 0.52±0.06****
Cerebellum 0.51±0.08 0.88±0.19** 0.49±0.07****
Cingulate/frontopolar cortex 0.31±0.05 0.48±0.20 0.47±0.06
Entorhinal cortex 0.33±0.07 0.41±0.12 0.46±0.07
Frontal cortex 0.33±0.08 0.40±0.13 0.51±0.06
Hippocampus 0.54±0.32 0.41±0.11 0.51±0.05
Medulla 0.61±0.12 1.29±0.42** 0.68±0.07***
Parietal/temporal/occipital cortex 0.33±0.08 0.40±0.10 0.51±0.06*
Pons 0.59±0.09 1.54±0.45** 0.67±0.08****
Striatum 0.31±0.06 0.40±0.13 0.53±0.04*
Peripheral tissues
Adrenals 10.49±2.22 10.12±3.01 4.90±0.17*
, ***
Bone 1.27±0.23 0.95±0.40 0.35±0.06*
, ***
Lung 6.97±0.63 8.83±3.82 1.11±0.16****
Plasma 0.22±0.05 0.18±0.03 0.56±0.09**
, ****
*pG0.05 as compared to control, **pG0.005 as compared to control, ***pG0.05 as compared to HSE, ****pG0.005 as compared to HSE
Table 3. Ex vivo biodistribution of [
11C]-DPA-713, expressed as standardized uptake values (SUV; mean ± SD), 60 min after tracer injection in control rats
(control; n=5), rats infected with HSV-1 (HSE; n=9), and rats infected with HSV-1 pre-treated with 5 mg/kg PK11195 5 min before tracer injection (HSE +
PK11195; n=4)
Control HSE HSE + PK11195
Brain
Amygdala/piriform cortex 0.31±0.09 0.36±0.19 0.24±0.12
Bulbus olfactorius 0.93±0.13 1.30±0.42 0.50±0.35***
Cerebellum 0.46±0.14 0.70±0.30 0.33±0.19
Cingulate/frontopolar cortex 0.17±0.04 0.32±0.22 0.40±0.44
Entorhinal cortex 0.20±0.05 0.33±0.19 0.23±0.10
Frontal cortex 0.23±0.16 0.26±0.15 0.25±0.18
Hippocampus 0.55±0.17 0.45±0.23 0.18±0.05*
Medulla 0.46±0.15 1.09±0.53* 0.31±0.17***
Parietal/temporal/occipital cortex 0.20±0.02 0.24±0.10 0.27±0.21
Pons 0.46±0.09 1.12±0.41** 0.28±0.08****
Striatum 0.16±0.02 0.28±0.15 0.18±0.04
Peripheral tissues
Adrenals 5.10±1.19 5.75±1.79 8.01±2.35
Bone 0.83±0.24 0.69±0.33 0.48±0.12
Lung 10.68±1.41 13.80±4.14 1.06±0.37**
, ****
Plasma 0.10±0.02 0.09±0.02 0.61±0.10**
, ****
*pG0.05 as compared to control, **pG0.005 as compared to control, ***pG0.05 as compared to HSE, ****pG0.005 as compared to HSE
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PK11195, resulting in a significant reduction in uptake,
whereas the uptake of [
11C]-DPA-713 and [
18F]-DPA-714
was only significantly blocked in the lungs, but not in the
adrenals.
Ex Vivo Biodistribution: Specific Binding
The ex vivo biodistribution showed an increased binding in
HSE rats as compared to controls and a decreased binding
after pre-treatment with PK11195, for all three PET tracers.
However, plasma levels of the tracer were also found to be
different between the three PET tracers and between treat-
ment groups. Since tracer accumulation in the brain is
dependent on tracer delivery (and thus tracer concentration)
from plasma, the brain uptake was corrected for plasma
radioactivity for each rat individually to calculate the tissue/
plasma ratios.
Non-specific binding and specific binding of [
11C]-(R)-
PK11195, [
11C]-DPA-713, and [
18F]-DPA-714 are displayed
in Table 5. Non-specific binding was defined as the tissue/
plasma ratio of rats pre-treated with PK11195. Specific
binding was calculated in control and HSE rats, by
subtracting the average tissue/plasma ratio of the HSE rats
pre-treated with PK11195 from the tissue/plasma ratio of
control and HSE rats, for each rat individually. The rationale
behind the definition of specific uptake is that the uptake in
rats pre-treated with PK11195 represents non-specific bind-
ing only, whereas the uptake in control and HSE rats is due to
both specific and non-specific binding. Non-specific binding
was found to be statistically significantly lower in almost all
brain areas for both [
11C]-DPA-713 and [
18F]-DPA-714,
when compared to [
11C]-(R)-PK11195. The specific binding
in control rats was found to be significantly higher for [
11C]-
DPA-713 in the amygdala/piriform cortex, bulbus olfactorius,
cerebellum, entorhinal cortex, medulla, parietal/temporal/
occipital cortex, pons, and striatum, when compared to
[
11C]-(R)-PK11195. For [
18F]-DPA-714, the specific uptake
in control rats was significantly higher than [
11C]-(R)-
PK11195 uptake in the cingulate/frontopolar cortex, pons,
and striatum. In addition, specific uptake in HSE rats was
found to be significantly higher for [
11C]-DPA-713 in the
amygdala/piriform cortex, bulbus olfactorius, entorhinal
cortex, hippocampus, medulla, and parietal/temporal/occipi-
tal cortex as compared to [
11C]-(R)-PK11195. No significant
differences in specific binding in HSE rats were found
between [
11C]-(R)-PK11195 and [
18F]-DPA-714.
The specific binding in control rats showed a good
correlation with [
3H]-PK11195 binding (Fig. 4) as was
measured by Kurumaji et al. [25] for all three PET tracers.
The best correlation was found for [
11C]-(R)-PK11195 that
had a R of 0.96 (p=0.0006), followed by [
11C]-DPA-713
with a R of 0.87 (p=0.01) and [
18F]-DPA-714 with a R of
0.77 (p=0.04). Although the best correlation was found for
[
11C]-(R)-PK11195, the slope of the linear regression was
highest for [
11C]-DPA-713 (0.016; compared to 0.010 for
[
11C]-(R)-PK11195 and 0.005 for [
18F]-DPA-714), which
indicates that [
11C]-DPA-713 uptake might be most sensitive
to changes in TSPO expression. Although these results seem
to depend on the bulbus olfactorius, which has the highest
uptake, the correlation remained good after removal of this
data point from the regression analysis. In addition, the slope
of the linear regression remained highest for [
11C]-DPA-713.
Discussion
In the present study, the new TSPO ligands [
11C]-DPA-713
and [
18F]-DPA-714 were evaluated in a rat model of herpes
Table 4. Ex vivo biodistribution of [
18F]-DPA-714, expressed as standardized uptake values (SUV; mean ± SD), 120 min after tracer injection in control rats
(control; n=5), rats infected with HSV-1 (HSE; n=9), and rats infected with HSV-1 pre-treated with 5 mg/kg PK11195 5 min before tracer injection (HSE +
PK11195; n=4)
Control HSE HSE + PK11195
Brain
Amygdala/piriform cortex 0.25±0.08 0.41±0.34 0.50±0.17
Bulbus olfactorius 0.55±0.09 0.88±0.30 0.85±0.35
Cerebellum 0.36±0.05 0.41±0.20 0.43±0.08
Cingulate/frontopolar cortex 0.20±0.02 0.33±0.21 0.45±0.11
Entorhinal cortex 0.20±0.04 0.39±0.32 0.44±0.11
Frontal cortex 0.17±0.02 0.21±0.09 0.40±0.10**
, ***
Hippocampus 0.35±0.25 0.39±0.16 0.48±0.14
Medulla 0.40±0.06 0.81±0.28* 0.45±0.08
Parietal/temporal/occipital cortex 0.17±0.02 0.19±0.05 0.38±0.09**
, ***
Pons 0.31±0.02 0.58±0.26 0.43±0.09
Striatum 0.18±0.01 0.32±0.22 0.49±0.18
Peripheral tissues
Adrenals 6.75±1.16 6.36±1.48 9.03±2.88
Bone 0.40±0.17 0.50±0.20 0.42±0.12
Lung 16.55±4.53 15.14±4.98 1.49±0.34**
, ***
Plasma 0.13±0.02 0.22±0.34 1.15±0.35**
, ***
*pG0.05 as compared to control, **pG0.005 as compared to control, ***pG0.005 as compared to HSE
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strated that [
11C]-DPA-713 has lower background binding
and has the potency to reach higher specific uptake in
infected brain tissue than [
11C]-(R)-PK11195. [
18F]-DPA-
714 showed low non-specific binding, but also lower
specific binding. Data from immunohistochemistry, in vivo
PET imaging, and ex vivo biodistribution corresponded
nicely for all tracers.
The TSPO that is only modestly expressed in the healthy
brain is upregulated in microglia cells when they become
activated in response to inflammatory stimuli and brain
damage. Microglia cells are increasingly associated with
neurological diseases, such as Parkinson’s disease [15] and
multiple sclerosis [9], and are therefore an important target
for early diagnosis and detection of the subtle effects of
therapeutic intervention. At present, the most widely used
PET tracer to visualize activated microglia is the TSPO
ligand [
11C]-(R)-PK11195, but this radiotracer may not
provide the required sensitivity. The high lipophilicity and
high non-specific binding of [
11C]-(R)-PK11195 result in a
low signal-to-noise ratio, which makes detecting mild
Table 5. Non-specific and specific binding of [
11C]-(R)-PK11195, [
11C]-DPA-713, and [
18F]-DPA-714
[
11C]-(R)-PK11195 [
11C]-DPA-713 [
18F]-DPA-714
Non-specific binding
Amygdala/piriform cortex 0.88±0.05 0.39±0.18* 0.47±0.21*
Bulbus olfactorius 0.94±0.11 0.81±0.53 0.80±0.40
Cerebellum 0.89±0.11 0.53±0.29 0.40±0.12*
Cingulate/frontopolar cortex 0.85±0.08 0.64±0.67 0.42±0.16
Entorhinal cortex 0.84±0.11 0.38±0.15** 0.41±0.15*
Frontal cortex 0.91±0.07 0.41±0.27* 0.37±0.13*
Hippocampus 0.93±0.10 0.30±0.06** 0.45±0.18**
Medulla 1.23±0.15 0.50±0.26** 0.41±0.13**
Parietal/temporal/occipital cortex 0.91±0.10 0.44±0.31* 0.35±0.13*
Pons 1.21±0.10 0.46±0.14** 0.40±0.14**
Striatum 0.97±0.10 0.30±0.04** 0.46±0.21**
Specific binding control
Amygdala/piriform cortex 0.69±0.64 2.62±0.71* 1.44±0.62
Bulbus olfactorius 4.64±2.22 8.28±1.37** 3.43±0.82
Cerebellum 1.50±0.73 3.90±1.20** 2.47±0.82
Cingulate/frontopolar cortex 0.57±0.26 1.06±0.35 1.12±0.25*
Entorhinal cortex 0.67±0.42 1.62±0.45** 1.20±0.62
Frontal cortex 0.57±0.29 1.85±1.62 0.96±0.35
Hippocampus 1.81±2.26 5.02±1.38 2.37±2.38
Medulla 1.56±0.70 3.93±1.45** 2.76±0.75
Parietal/temporal/occipital cortex 0.57±0.31 1.48±0.21* 1.00±0.38
Pons 1.51±0.72 4.05±0.81* 2.07±0.54
Striatum 0.46±0.27 1.22±0.15* 0.95±0.29*
Specific binding HSE
Amygdala/piriform cortex 1.38±0.63 3.87±2.58* 2.14±0.80
Bulbus olfactorius 8.39±3.64 14.44±5.66* 6.89±2.45
Cerebellum 4.36±1.85 7.72±3.68 3.66±2.80
Cingulate/frontopolar cortex 1.89±1.02 3.23±2.99 1.98±0.47
Entorhinal cortex 1.55±0.71 3.54±2.52* 2.09±0.46
Frontal cortex 1.37±0.59 2.64±2.01 1.30±0.28
Hippocampus 1.44±0.62 4.99±2.88** 3.01±0.79
Medulla 6.21±2.22 12.56±7.11* 7.18±3.90
Parietal/temporal/occipital cortex 1.37±0.40 2.44±1.37* 1.24±0.34
Pons 7.77±2.87 12.77±5.39 5.03±3.67
Striatum 1.39±0.98 3.06±2.07 1.80±0.50
Non-specific binding was defined as the tissue/plasma ratio of HSE rats pre-treated with PK11195 (n=4). The specific binding in control (n=5) and HSE
(n=9) rats werecalculatedby theequations[controltissue/plasma−averagepre-treatedtissue/plasma] and[HSEtissue/plasma −averagepre-treatedtissue/plasma],respectively
*pG0.05 and **pG0.005 as compared to [
11C]-(R)-PK11195
Fig. 4. Correlation of specific binding in control rats for
[
11C]-(R)-PK11195, [
11C]-DPA-713, and [
18F]-DPA-714 with
[
3H]-PK11195 binding as determined by Kurumaji et al. [25].
The R was 0.96 for [
11C]-(R)-PK11195 (p=0.0006; y=0.36+
0.010x), 0.87 for [
11C]-DPA-713 (p=0.0116; y=1.79+0.016x),
and 0.77 for [
18F]-DPA-714 (p=0.0427; y=1.35+0.005x).
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difficult.
The majority of studies that evaluate new radioligands for
the TSPO use striatum-lesioned models of neuroinflamma-
tion, in which a toxic substance, like quinolinic acid, kainic
acid, or 6-OH-DOPA, is stereotactically injected into the
striatum. The rat model of herpes encephalitis better mimics
neurological disorders as it does not involve invasive
manipulations, but induces microglia cell activation via a
biological process. In addition, HSV-1 is implicated in the
etiopathogenesis of neurological and psychiatric disorders,
like schizophrenia [26] and Alzheimer’s disease [26, 27] and
may be specifically involved in the focal neuroinflammatory
processes in these disorders. It has already been shown that
HSV-1 invasion of the brain is associated with the activation
of microglia cells [13, 28, 29]. Also in the present study, it
was confirmed by immunohistochemical staining that the
central nervous system invasion of HSV-1 results in intense
microglia activation, in the bulbus olfactorius, frontal cortex,
hippocampus, cerebellum, and brainstem. The pattern of this
microglia activationisconsistentwiththe findingsofBarnettet
al. [30], who showed that intranasal inoculation of mice with
HSV-1 resulted in the spread of HSV-1 to the hippocampus,
amygdala, midbrain, and brainstem via the olfactory bulb. The
severe activation of microglia cells in the brainstem may be
caused by indirect HSV-1 invasion of the brainstem via the
neural pathway from the bulbus olfactorius to the locus
coeruleus[30,31]orbydirectinvasionofthesensorytrigeminal
nuclei via the main sensory nerve of the face, the trigeminal
nerve.Inaddition,microgliacellactivationinthe brainstem may
also be caused by HSV-1 invasion of the trigeminal nerve,
resulting in activation of microglia cells surrounding the
anterograde nerve connections [32]. Although the rat model of
herpes encephalitis represents a more physiological model of
microglia activation, a disadvantage of the model compared to
striatumlesionmodelsisthevariabilityintheextentofmicroglia
activation. Despite the variation in the extent of microglia cell
activation, it was shown that the brainstem was affected in all
rats. One way to reduce some variation in measurement of
microglia cell activation would be to compare the different PET
tracers in the same rat. However, due to the severity of the
disease, the degree of microglia cell activation can change
quickly within the time period between the PET scans which
makes it difficult compare the tracers in the same rat.
The uptake of [
11C]-(R)-PK11195, [
11C]-DPA-713, and
[
18F]-DPA-714 was determined by both PET scanning and
ex vivo biodistribution. Uptake values derived from the PET
scan were on average higher than the values obtained from ex
vivo biodistribution, but this difference was statistically not
significant. The small difference between both techniques can
probably be attributed to tissue kinetics, since the ex vivo
biodistribution represents a single time point, whereas the
values obtained from the PET scan represent an average of
10 min. In regions with a high uptake and thus slower
washout, like the bulbus olfactorius, this results in PET values
lower than the ex vivo biodistribution values. For brain
regions with lower uptake and faster washout, and thus a
largerchangewithin10min,thisresultsinPETvaluesthatare
lower or equal to the ex vivo biodistribution values.
In the present study, it was shown that the standardized
uptake value of [
11C]-DPA-713 is significantly lower in
healthy brain tissue as compared to the uptake of [
11C]-(R)-
PK11195.Thissuggestsless non-specific binding.Indeed,pre-
treatment with PK11195 showed that [
11C]-DPA-713 has
lower non-specific binding than [
11C]-(R)-PK11195. This
could be explained by the lower lipophilicity of DPA-713 than
thatofPK11195(LogP2.4vs.3. 4[22]).InbrainareasinHSV-
infectedanimals whereactivationofmicroglia cells wasfound,
[
11C]-DPA-713 uptake was comparable to the uptake of [
11C]-
(R)-PK11195. Thus, the lower non-specific binding and
comparable uptake in infected areas results in a higher signal-
to-noise ratio of [
11C]-DPA-713 than of [
11C]-(R)-PK11195,
suggesting that [
11C]-DPA-713 is more suitable for the
detection ofmildneuroinflammation.The results ofthe present
study are consistent with the findings of Boutin et al. [23]. In
their study, it was also shown that the signal-to-noise ratio of
[
11C]-DPA-713 is higher than that of [
11C]-(R)-PK11195, due
to a reduced uptake in healthy tissue for [
11C]-DPA-713.
In healthy brain tissue, the standardized uptake value of
[
18F]-DPA-714 is significantly lower than the uptake of both
[
11C]-(R)-PK11195 and [
11C]-DPA-713. In addition, the
non-specific binding of [
18F]-DPA-714 was found to be
lower than the non-specific [
11C]-(R)-PK11195 binding.
This suggests that this radiotracer is potentially suitable for
visualizing mild neuroinflammation. Although [
18F]-DPA-
714 is able to visualize neuroinflammation in our rat model
of herpes encephalitis and also in a striatum-lesioned model
[19, 20], the uptake in infected brain areas is significantly
lower as compared to [
11C]-(R)-PK11195.
Although the standardized uptake value is widely used to
display the uptake of tracers, it does not correct for the
activity in plasma, and thus, not for tracer delivery to the
brain. This could lead to a wrong interpretation of the data
when comparing the tracers in different conditions. Ideally,
the binding potential or distribution volume of the tracers
should be determined using plasma input on different time
points during the scan. However, plasma samples are
difficult to obtain, especially in severely ill animals. There-
fore, in the present study, the tissue/plasma ratios were
calculated from a single ex vivo plasma activity measure-
ment. After correction for plasma activity, the specific
binding in both control and HSE rats was found to be
significantly higher for [
11C]-DPA-713 than for [
11C]-(R)-
PK11195. In contrast to [
11C]-(R)-PK11195, [
11C]-DPA-713
is even able to show specific binding to the low basal
expression levels of TSPO in control rats. In addition, the
greater slope of the correlation between tracer uptake and
TSPO expression (Fig. 4) suggests that [
11C]-DPA-713 is
more sensitive for small changes in the amount of TSPO as
compared to [
11C]-(R)-PK11195. Thus, this study indicates
that [
11C]-DPA-713 is more sensitive for visualizing neuro-
inflammation than [
11C]-(R)-PK11195.
396 J. Doorduin et al.: New PET Tracers for TSPO ImagingAlthough [
18F]-DPA-714 showed low non-specific bind-
ing, specific binding of [
18F]-DPA-714 was much lower than
that of [
11C]-DPA-713, even after correction for plasma
activity. Interestingly, a recent study in a striatum lesion
model showed that the tissue uptake ratio between the
control and lesioned striatum was higher for [
18F]-DPA-714
than for [
11C]-(R)-PK11195, with three times higher binding
potential of [
18F]-DPA-714 [33]. Moreover, in the present
study, [
18F]-DPA-714 binding (SUV) in infected brain areas
was not effectively blocked by pre-treatment with PK11195,
while [
18F]-DPA-714 uptake in the striatum lesion model
was inhibited by pre-treatment with PK11195, DPA-713,
and DPA-714 [20, 22]. The apparent discrepancy between
the results of our study and those of the previous studies in
the striatum lesion model might be due to differences in the
affinity state of the receptor between both animal models.
[
18F]-DPA-714 is an agonist of the TSPO and an agonist
usually binds only to the high affinity state of the receptor.
Microglia cell activation in the striatum lesion model has a
more chronic, neurodegenerative character, as microglia
cells are mainly involved in removing the debris of the
neuronal cells that were destroyed by the chemical com-
pound. In the HSE model, the activated microglia cells are
involved in a more acute response by combating the
exogenous pathogen and thus they have a more neuro-
protective role. One could speculate that the affinity state of
the TSPO depends on the neuroprotective or neurodegener-
ative activity of the microglia cells. The chronically
activated (neurodenerative) microglia cells may contain
more TSPO in the high affinity state, which would result
in better binding of [
18F]-DPA-714. If this hypothesis could
be confirmed, TSPO, agonists like [
18F]-DPA-714, may be
important radiotracers to visualize an important aspect of
neuroinflammation.
Another remarkable finding in this study was that the
binding of [
18F]-DPA-714 and [
11C]-DPA-713 in the
adrenals could not be blocked by pre-treatment with
PK11195, whereas pre-treatment did block the binding of
[
11C]-(R)-PK11195. For [
18F]-DPA-714, similar results were
found by James et al. [19, 20]. This observation suggests the
presence of an alternative binding site for DPA-713 and
DPA-714 that is predominantly expressed in the adrenals
and does not bind PK1115. Whether the alternative binding
site in the adrenals could be a hitherto unknown subtype of
the TSPO, or another receptor, remains to be elucidated.
Conclusion
The present results showed that [
11C]-DPA-713 is a
promising new radioligand for TSPO expression in activated
microglia due to its low non-specific binding in the brain.
This tracer appears to be a more sensitive tool to detect small
changes in TSPO expression than [
11C]-(R)-PK11195. To
validate superiority of [
11C]-DPA-713 over [
11C]-(R)-
PK11195 in quantification of neuroinflammation, clinical
studies in neurological diseases that are associated with
microglia cell activation are needed. Although there may be
differences in the affinity state of the TSPO between
previous animal models using [
18F]-DPA-714 and the
present study, the fact that this radioligand is an agonist of
the TSPO may open new possibilities in PET imaging of
neuroinflammation, which warrants its further evaluation.
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